ClinConnect ClinConnect Logo
Search / Trial NCT06464536

Evaluation of the Efficacy of Compression With Tight Surgical Gloves in Patients With Taxane-based Therapy

Launched by ST.GALLEN UNIVERSITY OF APPLIED SCIENCES · Jun 13, 2024

Trial Information

Current as of July 04, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is investigating whether wearing tight surgical gloves can help reduce a condition called peripheral neuropathy in patients receiving a type of cancer treatment known as taxane therapy. Peripheral neuropathy can cause symptoms like pain, tingling, or numbness in the hands and feet, which can be uncomfortable for patients. The study aims to see if the compression from the gloves can ease these symptoms during treatment.

To be eligible for this trial, participants must be adults aged 65 to 74 who are starting their first treatment with taxanes for certain cancers, such as breast cancer or urogenital cancer. They must also be able to understand the study information in German or English and provide consent to participate. However, individuals with a history of neuropathy from other causes or those taking specific medications that could affect nerve function will not be able to join. If you participate, you can expect to wear the gloves during your treatment sessions and help researchers learn if this simple approach can improve comfort for patients undergoing taxane therapy.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Mamma or Urogenital carcinoma
  • first treatment with Taxanes (nab-Paclitaxel, Paclitaxel, Docetaxel)
  • signed informed consent
  • sufficient proficiency in German or English
  • Exclusion Criteria:
  • other therapy that could have caused peripheral neuropathy within the last 24 months (Taxane, Platin, Vincaalkaloids, etc.)
  • History of neuropathy such as Raynaud's phenomenon, fibromyalgia and diabetic polyneuropathy
  • Use of polyneuropathy medications including duloxetine; gabapentin/pregabalin; topical amitriptyline, ketamine, baclofen; oral cannabinoids; tricyclic antidepressants; and ganglioside monosialic acid
  • such impaired cognition that prevents participation in the study according to the assessment of the caregivers

About St.Gallen University Of Applied Sciences

St. Gallen University of Applied Sciences is a leading institution dedicated to advancing education and research in applied sciences, with a strong emphasis on innovation and practical solutions in healthcare. The university actively engages in clinical trials to explore and validate new methodologies and technologies that enhance patient care and outcomes. Through collaboration with industry partners and healthcare professionals, St. Gallen University of Applied Sciences aims to translate research findings into real-world applications, contributing to the advancement of medical science and the improvement of health systems.

Locations

Zürich, , Switzerland

Patients applied

0 patients applied

Trial Officials

Anna Götz, PhD

Principal Investigator

USZ

Antje Koller, PhD

Principal Investigator

St.Gallen University of Applied Sciences

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported